1Mantadakis E,Samonis G,Kalmanti M. A comprehensive review of acute promyelocytic leukemia in children[J].Acta Haematologica,2008,(02):73-82.
2Matasar MJ,Ritchie EK,Consedine N. Incidence rates of acute promyelocytic leukemia among Hispanics,blacks,Asians,and non-Hispanic whites in the United States[J].European Journal of Cancer Prevention,2006,(04):367-370.doi:10.1097/00008469-200608000-00011.
3Ribeiro RC,Rego E. Management of APL in developing countries:epidemiology,challenges and opportunities for international collaboration[J].Hematology(American Society Hematology Education Program),2006.162-168.
4Albano F,Mestice A,Pannunzio A. The biological characteristics of CD34 + CD2 + adult acute promyelocytic leukemia and the CD34 CD2 hypergranular(M3) and microgranular (M3v) phenotypes[J].Haematologica,2006,(03):311-316.
5Sanz MA,Tallman MS,Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia[J].Blood,2005,(08):3019-3025.doi:10.1182/blood-2004-09-3475.
6Lo-Coco F,Ammatuna E. The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment[J].Hematology(American Society Hematology Education Program),2006.156-161,514.
7Redner RL. Variations on a theme:the alternate translocations in APL[J].Leukemia:Official Journal of the Leukemia Society of America,Leukemia Research Fund,U.K,2002,(10):1927-1932.
8Grimwade D,Lo-Coco F. Acute promyelocytic leukemia:a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia[J].Leukemia:Official Journal of the Leukemia Society of America,Leukemia Research Fund,U.K,2002,(10):1959-1973.
9Stein E,McMahon B,Kwaan H. The coagulopathy of acute promyelocytic leukaemia revisited[J].Best Practice and Research:Clinical Rheumatology,2009,(01):153-163.
10Zhou GB,Zhang J,Wang ZY. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and Arsenic trioxide:a paradigm of synergistic molecular targeting therapy[J].Philosophical Transactions Of the Royal Society of London Series B Biological Sciences,2007,(1482):959-971.
4Mistry AR, Pedersen EW, Solomon E, Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev. 2003, 17(2): 71-97.
5Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto J J, Gardin C, Makhoul PC, Travade P, Solary E,Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999; 94(4): 1192-1200.
6Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-transretinoie acid in acute promyeloeytic leukemia. N Engl J Med. 1997, 337(15): 1021-1028.
7Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008, 111 (5) : 2505-2515.
8Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A. Differentiation therapy of acute promyeloeytic leukemia with tretinoin (all-transretinoic acid). N Engl J Med. 1991, 324(20): 1385- 1393.
9Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol. 2005- 23(10) : 2396-2410.
10Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z. Use of arsenic trioxide (As2O3 ) in the treatment of acute promyelocytic leukemia (APL): T. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997; 89(9): 3345-3353.
